Table 2. Baseline characteristics of all patients with r-axSpA and nr-axSpA at recruitment in SCQM.

Parameter	nr-axSpA N = 431	r-axSpA N = 1155	P
Female sex, %	53.8	30.6	<0.001
Age, years	37.1 (10.8)	40.3 (11.3)	<0.001
Symptom duration, years	8.8 (9.4)	15.0 (11.1)	<0.001
HLA-B27 positive, %	73.1	81.5	<0.001
BASDAI	5.0 (2.2)	4.7 (2.2)	0.14
ASDAS	2.9 (0.9)	3.1 (1.1)	0.02
CRP (mg/l), median (IQR)	4.5 (2.0; 8.0)	8.0 (3.0; 15.0)	<0.001
Elevated CRP, %	27.9	48.1	<0.001
BASFI	3.1 (2.4)	3.6 (2.6)	<0.001
BASMI	1.3 (1.3)	2.5 (2.2)	<0.001
EQ-5D	59.6 (20.9)	60.4 (22.4)	0.49
Current peripheral arthritis, %	38.7	31.6	0.01
Current enthesitis, %	73.5	65.1	0.002
On methotrexate, %	7.9	7.6	0.83
On sulfasalazine, %	5.3	4.8	070
On NSAIDs, %	89.5	88.6	0.64
On TNFi, %	13.9	22.8	0.002
Current smokers, %	31.1	40.6	0.001
BMI	24.7 (4.2)	25.3 (4.5)	0.01
Number exercise sessions per week, median (IQR)	2.0 (0.0; 4.0)	2.0 (0.0; 4.0)	0.92

Values are the mean (SD), except where indicated otherwise. ASDAS = Ankylosing Spondylitis Disease Activity Score; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; C-reactive protein (CRP) levels; EQ-5D = EuroQol 5-domain; HLA-B27 = human leucocyte antigen B27; MASES = Maastricht Ankylosing Spondylitis Enthesitis Score; modification refers to the inclusion of the plantar fascia in the count; nr-axSpA = nonradiographic axial spondyloarthritis; NSAIDs = Nonsteroidal anti-inflammatory drugs; r-axSpA = radiographic axial spondyloarthritis; TNFi = Tumour necrosis factor inhibitor.